Related Experiment Video

Updated: May 21, 2026

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings
19:57

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings

Published on: March 30, 2014

Managing drug resistance in cancer: lessons from HIV therapy

Christoph Bock1, Thomas Lengauer

  • 1CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria. cbock@cemm.oeaw.ac.at

Nature Reviews. Cancer
|June 8, 2012
PubMed

Insights

Drug resistance in HIV and cancer poses treatment challenges. HIV therapy

Area of Science:

  • Oncology
  • Virology
  • Genetics

Background:

  • Drug resistance is a major cause of treatment failure in both HIV infection and cancer.
  • High mutation rates in HIV and the genetic diversity of cancers drive the emergence of resistant strains and cells.
  • Somatic evolution allows drug-resistant cancer cells to outcompete susceptible ones.

Purpose of the Study:

  • To explore the potential of patient-specific combination therapies in cancer treatment.
  • To propose HIV therapy as a model for developing personalized cancer treatments.
  • To highlight the parallels between HIV drug resistance and cancer drug resistance.

Main Methods:

  • Review of current strategies for treating drug-resistant HIV infection.
  • Analysis of the mechanisms of drug resistance in both HIV and cancer.
  • Comparison of patient-specific combination therapy approaches.

Main Results:

  • Patient-specific combination antiviral therapy is effective for drug-resistant HIV.
  • Genotype-based predictions guide the selection of optimal HIV drug combinations.
  • Cancer shares characteristics with HIV, including genetic diversity and the evolution of resistance.

Conclusions:

  • The success of personalized HIV therapy offers a blueprint for personalized cancer treatment strategies.
  • Adapting HIV treatment models could accelerate the development of effective combination therapies for cancer.
  • Personalized, genotype-guided combination therapies hold promise for overcoming drug resistance in both HIV and cancer.

More Related Videos

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors05:46

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Published on: April 9, 2014

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...